Search the site

News & Events

National study to unravel triggers for childhood leukaemia

A national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.

News & Events

New clinical trial to improve outcomes for babies with leukaemia

The Australian arm of an international clinical trial looking at improved treatments for young babies with leukaemia has been awarded funding from the MRFF.

People

Associate Professor Rishi S. Kotecha

Co-Head, Leukaemia Translational Research

People

Professor Ursula Kees

Honorary Emeritus Fellow

News & Events

New study exposes link between pesticides and childhood brain tumours

A new Telethon Institute study has revealed a potential link between pesticide treatments in the home and a higher risk of children developing brain tumours.

News & Events

Exposure to diesel exhaust increases risk of child brain tumours

Research at Telethon Institute has shown a correlation between brain tumours in young children and their parents' exposure to diesel exhaust fumes before birth.

News & Events

Researchers find new insight into genetics of aggressive cancer

Researchers at Telethon Institute have found genetic differences in the rare and aggressive NUT-midline carcinoma, presenting new treatment opportunities.

News & Events

Telethon Adventurers fund new brain tumour research fellowship

The Telethon Adventurers have announced a new research fellowship to investigate the genes involved in childhood brain tumours.

News & Events

Perth researchers decipher genetic pattern that predicts leukaemia relapse

Cancer researchers at Perth's The Kids for Child Health Research have discovered a genetic pattern that predicts the likelihood of relapse

Research

Vincristine Induced Adverse Effects in Lymphoma Bearing Dogs With Asymptomatic Neutropenia at the Time of Drug Administration

Vincristine sulphate, a microtubule inhibitor, is used extensively in veterinary oncology for treating lymphoma. Neutropenia during multiagent protocols is a common reason for treatment delay and reduced dose intensity. This study evaluated toxicities associated with treating systemically well neutropenic lymphoma patients with vincristine.